近視治療鏡片進階論壇 Forum for Advanced Myopia Management Lenses
14 Dec 2025
14:00
16:30
林慧茹 Hui-Ju LinTaiwan
Moderator
Advances in Artificial Intelligence Models and Algorithms in Amblyopia and Strabismus Review of Artificial Intelligence (AI) models that detect strabismus and amblyopia risk factors from smartphone photos, videos, and images, facilitating large-scale, accessible community screening. Discussion on how AI is personalizing amblyopia therapy, thereby maximizing efficacy and engagement. Critical appraisal of the requirements for clinical validation, regulatory approval, and the ethical integration of these AI tools into standard ophthalmic practice.
AI is poised to fundamentally reshape the management of strabismus and amblyopia by introducing unprecedented levels of objectivity, accessibility, and personalization. the knowledge to understand, evaluate, and eventually integrate these powerful technologies into their practice to improve patient outcomes. AI screening and diagnosis to treatment optimization and monitoring.
蔡紫薰 Tzu-Hsun TsaiTaiwan
Moderator
Facts and Myths: What We Need to Know About Atropine Eye DropsA study conducted in Taiwan during the 1990s demonstrated that atropine reduced myopia progression in a dose-dependent manner. Since that time, the clinical use of atropine in school-aged children has been widespread in Taiwan for more than two decades. Owing to this long history of high-concentration atropine prescriptions, Taiwan represents a distinctive setting in which to evaluate the long-term safety of atropine use. Using data from a large cohort within the NHIRD, we found that the incidence of ocular complications was higher among individuals with myopia compared with those without. However, among participants with myopia, the incidence of these complications did not differ between atropine users and nonusers, and higher cumulative doses of atropine were not associated with increased risk.
The long-term efficacy of atropine eye drops for myopia control also merits further investigation. The LAMP clinical trial demonstrated that continuous treatment with 0.05% atropine effectively controlled myopia progression over five years. In contrast, the ATLAS from Singapore reported that topical atropine use during childhood was not associated with long-term ocular complications; however, its long-term efficacy in myopia control was less conclusive. Furthermore, recent randomized clinical trials have yielded inconsistent findings regarding the effectiveness of low-dose atropine, and regulatory approval by the U.S. FDA remains pending. Further research is therefore warranted to refine atropine treatment strategies, including the optimal timing of initiation, adjustment of concentration, duration of therapy, and methods and timing of discontinuation. Most importantly, future work should aim to clarify the ultimate clinical significance and long-term benefits of atropine therapy for myopia control.
接軌國際：IMI 近視前期定義與台灣經驗分享Pre-myopia is an emerging concept in myopia prevention, referring to children within a specific age range who exhibit refractive errors that, along with certain risk factors, place them at increased risk of developing myopia and who may benefit from early intervention. This presentation focuses on the international definitions of pre-myopia and utilizes public health survey data and clinical evidence from Taiwan to analyze the prevalence of pre-myopia and explore issues related to myopia development.